Ibandronic acid

Ibandronic acid
Clinical data
Trade names	Boniva, Bonviva, Bondronat, others
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN; US DailyMed: Ibandronate_sodium; US FDA: Ibandronate_sodium;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth, intravenous
ATC code	M05BA06 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	0.6%
Protein binding	90.9 to 99.5%; (concentration-dependent)
Metabolism	Nil
Elimination half-life	10 to 60 hours
Excretion	Kidney
Identifiers
	IUPAC name Hydroxy-[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphinate;
CAS Number	114084-78-5 ;
PubChem CID	60852;
IUPHAR/BPS	3059;
DrugBank	DB00710 ;
ChemSpider	54839 ;
UNII	UMD7G2653W;
KEGG	D08056 ; as salt: D04486 ;
ChEBI	CHEBI:93770;
ChEMBL	ChEMBL997 ;
PDB ligand	BFQ (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID5048340 ;
ECHA InfoCard	100.214.537
Chemical and physical data
Formula	C9H23NO7P2
Molar mass	319.231 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=P(O)(O)C(O)(CCN(CCCCC)C)P(=O)(O)O;
	InChI InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17) ; Key:MPBVHIBUJCELCL-UHFFFAOYSA-N ;
	(what is this?) (verify)

Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. It may also be used to treat hypercalcemia (elevated blood calcium levels). It is typically formulated as its sodium salt ibandronate sodium.

It was patented in 1986 by Boehringer Mannheim and approved for medical use in 1996.